BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17646281)

  • 1. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity.
    Perkins EJ; Abraham T
    Drug Metab Dispos; 2007 Oct; 35(10):1903-9. PubMed ID: 17646281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
    Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
    Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
    J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies.
    Eriksson AH; Varma MV; Perkins EJ; Zimmerman CL
    J Pharm Sci; 2010 Mar; 99(3):1574-81. PubMed ID: 19780137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
    Bueno AB; Collado I; de Dios A; Domínguez C; Martín JA; Martín LM; Martínez-Grau MA; Montero C; Pedregal C; Catlow J; Coffey DS; Clay MP; Dantzig AH; Lindstrom T; Monn JA; Jiang H; Schoepp DD; Stratford RE; Tabas LB; Tizzano JP; Wright RA; Herin MF
    J Med Chem; 2005 Aug; 48(16):5305-20. PubMed ID: 16078848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs.
    Johnson JT; Mattiuz EL; Chay SH; Herman JL; Wheeler WJ; Kassahun K; Swanson SP; Phillips DL
    Drug Metab Dispos; 2002 Jan; 30(1):27-33. PubMed ID: 11744608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of a potent group II metabotropic glutamate receptor agonist, in rats, dogs, and monkeys.
    James JK; Nakamura M; Nakazato A; Zhang KE; Cramer M; Brunner J; Cook J; Chen WG
    Drug Metab Dispos; 2005 Sep; 33(9):1373-81. PubMed ID: 15980102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist.
    Nakamura M; Kawakita Y; Yasuhara A; Fukasawa Y; Yoshida K; Sakagami K; Nakazato A
    Drug Metab Dispos; 2006 Mar; 34(3):369-74. PubMed ID: 16326817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
    Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
    Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
    Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
    J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
    Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
    Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine.
    Sun Y; Sun J; Shi S; Jing Y; Yin S; Chen Y; Li G; Xu Y; He Z
    Mol Pharm; 2009; 6(1):315-25. PubMed ID: 19115956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.
    Pak YA; Long AJ; Annes WF; Witcher JW; Knadler MP; Ayan-Oshodi MA; Mitchell MI; Leese P; Hillgren KM
    Drug Metab Dispos; 2017 Feb; 45(2):137-144. PubMed ID: 27895114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
    Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability and pharmacokinetics.
    Cao F; Jia J; Yin Z; Gao Y; Sha L; Lai Y; Ping Q; Zhang Y
    Mol Pharm; 2012 Aug; 9(8):2127-35. PubMed ID: 22352697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.